Novavax Eyes New Partnerships as Sanofi Advances COVID-Flu Vaccine Trial

Novavax logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Sanofi has begun a Phase 3 European study of its combined COVID-19 and flu vaccine for adults over 60, and plans a U.S. Phase 3 study in 2027. Novavax could earn a $225 million milestone if the vaccine reaches its first U.S. sale, plus royalties.
  • Novavax is shifting toward licensing its vaccine technology and Matrix-M adjuvant through partners such as Pfizer, Sanofi, Takeda, and Serum Institute of India. It is also seeking to turn adjuvant testing agreements into licensing deals, though new partnerships are not guaranteed.
  • Novavax has started FDA pre-IND work and manufacturing for its C. difficile vaccine, with a clinical trial possible as early as 2027. The company says it has at least three years of cash and targets non-GAAP profitability by 2029.
  • Five stocks we like better than Novavax.

Novavax NASDAQ: NVAX is looking to expand partnerships around its vaccine technology while advancing a potential C. difficile vaccine and supporting partner Sanofi’s development of a combination COVID-19 and flu shot, executives said at the Jefferies 2026 Global Healthcare Conference in London.

CEO John Jacobs said Novavax has shifted from selling a single COVID-19 vaccine to licensing its technology to other companies. The approach relies on partners’ resources and expertise to develop vaccines across infectious diseases and, potentially, oncology.

Jacobs said Novavax’s 2026 achievements included a deal with Pfizer carrying a $30 million upfront payment and potential milestones across two fields, with a headline value of about $500 million. The company also earned a $125 million milestone after Sanofi initiated a combination vaccine trial in Europe.

Sanofi combination vaccine moves forward

Sanofi has started a Phase 3 immunogenicity study in Europe of a combination influenza and COVID-19 vaccine in people over 60, Chief Strategy Officer Elaine O’Hara said. She added that Sanofi has stated its intention to begin a Phase 3 study in the United States in 2027.

Novavax could receive a $225 million milestone if a combination vaccine using its COVID-19 shot achieves a first sale in the U.S., followed by royalties, Jacobs said. Head of R&D Bob Walker said Novavax could not comment on the design of the planned U.S. study because it does not have access to Sanofi’s plans beyond what the partner states publicly or confirms to Novavax.

O’Hara said Sanofi, which began its collaboration with Novavax in 2024, has placed the standalone Nuvaxovid COVID-19 vaccine in major U.S. retailers for the 2026 season. Retail pilots showed reordering and significant share in some locations where the vaccine was preferentially offered, she said.

CFO Jim Kelly estimated that global COVID-19 vaccine sales were $6.8 billion last year, including $2.9 billion in the U.S. He said U.S. demand this season had declined by a single-digit percentage so far, although recent weeks had exceeded the prior year.

Partnerships and pipeline

Novavax is also working to convert material transfer agreements, under which companies can test its Matrix-M adjuvant in their own laboratories, into licensing deals. Jacobs identified Takeda, Sanofi, Pfizer and Serum Institute of India as existing partners.

O’Hara said Novavax had generated positive preclinical oncology data internally and with an external company. An oncology company is also conducting preclinical experiments under a material transfer agreement, she said. Jacobs cautioned that not every experiment or agreement would lead to a deal and declined to predict when new partnerships might be signed.

For its internal C. difficile vaccine candidate, Novavax has begun the pre-investigational new drug process with the U.S. Food and Drug Administration and started manufacturing product for a potential clinical trial as early as 2027, Walker said. The company intends to license the vaccine, though O’Hara said retaining rights could also be considered as data become available.

Financial objectives

Kelly said Novavax has at least three years of cash and aims to pay off legacy advance purchase agreement liabilities by the first quarter of 2029. The company is targeting non-GAAP profitability as early as 2029 and a leaner model of $150 million to $200 million by 2028, he said.

Jacobs said potential developments in 2027 and beyond include new or expanded partnerships, additional data on Matrix-M and progress in Sanofi’s combination vaccine trials. He emphasized that the timing and success of those developments are uncertain.

About Novavax (NASDAQ:NVAX)

Novavax, Inc. is a biotechnology company focused on developing vaccines for infectious diseases. Its technology combines recombinant protein-based vaccine antigens with Matrix-M, a saponin-based adjuvant designed to strengthen the immune response. The company's best-known product is Nuvaxovid, a protein-based COVID-19 vaccine authorized in the United States and other markets. Novavax also develops additional vaccine candidates, including a combination COVID-19 and influenza vaccine. Founded in 1987 and headquartered in Gaithersburg, Maryland, Novavax serves international markets through regulatory approvals and commercial partnerships.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Novavax Right Now?

Before you consider Novavax, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novavax wasn't on the list.

While Novavax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines